Day 3Wednesday, 30 April 2025 - ET (Eastern Time, GMT-05:00)

• How to prepare and write compelling presentations: discover the secrets of brilliant presenting
• How to grab and maintain attention: make sure your audience is hearing what you want them to hear
• How to look and sound impressive: learn the tricks that the best presenters use

• Navigate the roles of Compliance, finance, and investor relations
• Uncover relevant risk areas and overcome key challenges that could arise during joint ventures and M&A
• Assess the impact of CIAs during M&A
• Key considerations including DOJ Guidance
• Integration phase – Experience post-acquisition impact on employee and Compliance framework
• How to prepare for being acquired and to acquire another company

• Dissecting practical approaches of successful campaigns
• How to cultivate a culture of Compliance: from creating open lines of communication to overcoming information barriers
• Practical campaign insight: what components were most beneficial in building awareness?
• How do you become ‘the voice’ of Ethics and Integrity in your organization?

The Trump Administration has dramatically shifted the focus of US enforcement activity.

Ethics and Compliance teams in pharmaceuticals are asking themselves whether they should also shift focus. Should they focus more on the risks they may be exposed to in relation to drug cartels and transnational crime organizations; or on forced labor that may exist in their supply chain?

Meanwhile anti-corruption laws around the world - including the FCPA - remain in place and an effective compliance program is still essential.

This session will highlight how compliance teams are adapting to the need to remain agile and the need to add new areas of risk to their focus, rather than simplify shifting.

It will provide practice insights on how effective compliance teams are using their limited resources to cover a broader range of activities.